

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of BOYD et al.

International Application No.: PCT/EP2003/015004

International Filing Date: December 10, 2003

For: 5-Hydroxytryptamine Transporter Gene Polymorphisms

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. _____ PCT/EP2003/015004 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:


- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

Express Mail Label No.: EV332065655US

Date of Mailing: 6/9/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.


Patty Wilson

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Virginia O. Campen
Attorney of Record
Registration No. 37,092

Date: 8 June 2005
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1012
Facsimile: (919) 483-7988

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

| | |
|----------------------------|-------------|
| SERIAL NO. | |
| FILING DATE | |
| APPLICANT | BOYD et al. |
| GROUP | |
| EXAMINER | |
| ATTORNEY DOCKET NO. | PG5043USw |

U.S. PATENT DOCUMENTS

| Examiner Initials | | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|----------------------|--|------------------|------------|------|-------|----------|-------------------------------|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Continue on page _____

FOREIGN PATENT DOCUMENTS

| | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes No |
|--|--|--------------------|---------------------|---------|-------|----------|-------------------------|
| | | WO01/61039 | 8/23/2001 | PCT | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

| | | |
|--|--|---|
| | | TATE, Baculovirus-mediated expression of neurotransmitter transporters, Methods in Enzymology 296:443-445 (1998). |
| | | LESCH et al., Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region, Science 274(5292):1527-1531 (1996). |
| | | PATA et al., Serotonin transporter gene polymorphism in irritable bowel syndrome, American J. of Gastroenterology 97(7):1780-1784 (2002). |
| | | FARTHING, Irritable bowel syndrome: new pharmaceutical approaches to treatment, Baillière's Clinical Gastroenterology, 13(3):461-471 (1999). |
| | | FURLONG et al., Analysis and Meta-Analysis of Two Serotonin Transporter Gene Polymorphisms in Bipolar and Unipolar Affective Disorders, Am. J. of Med. Genetics (Neruopsy. Genetics) 81:58-63 (1998). |
| | | GELERNTER et al., Linkage mapping of serotonin transporter protein gene SLC6A4 on chromosome 17, Hum Genet 95:677-680 (1995). |
| | | HEILS et al., Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene, J. of Neural Transmission (Gen Sect) 102:247-254 (1995). |
| | | HEILS et al., Allelic Variation of Human Serotonin Transporter Gene Expression, J. of Neurochemistry 66:2621-2624 (1996). |
| | | LESCH et al., Isolation of a cDNA encoding the human brain serotonin transporter, J. Neural Transm (GenSect) 91:67-72 (1993). |
| | | LESCH et al., Association of anxiety-related traits with a polymorphism in the Serotonin Transporter Gene Regulatory Region, Science 274:1527-1531 (1996). |
| | | MENZA et al., Depression and Anxiety in Parkinson's Disease: Possible Effect of Genetic Variation in the Serotonin Transporter, J. of Geriatric Psychiatry and Neurology 12:49-52 (1999). |
| | | RAMAMOORTHY et al., Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization, Proc. Natl. Acad. Sci. USA 90:2542-2546 (1993). |
| | | ROSENTHAL et al., Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder, Molecular Psychiatry 3:175-177 (1998). |

Continue on page _____

| | |
|-----------------|------------------------|
| EXAMINER | DATE CONSIDERED |
|-----------------|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.